Similarly, relationships between PIK3CA mutations and responses to anti-EGFR mAb remain controversial [22, 23, 31], and the present data showed no differences in Sym004 sensitivity between PIK3CA mutant and wild-type cancer cells. The gene discussed is PIK3CA; the disease is cancer.